Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection

Trial Profile

A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VE 303 (Primary)
  • Indications Clostridium difficile infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CONSORTIUM
  • Sponsors Vedanta Biosciences
  • Most Recent Events

    • 23 Sep 2019 According to a Vedanta Biosciences media release, the funding from recent series C-2 financing ($16.6 million) will support this trial.
    • 12 Sep 2019 Planned number of patients changed from 146 to 300.
    • 12 Dec 2018 Status changed from planning to recruiting, according to a PureTech Health media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top